Iterum Therapeutics Plc
ITRM
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.6M
Close$
$-1.09
3722.7% downside
Current Fair Value
3722.7% downsideOvervalued by 3722.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.60 Million |
|---|---|
| Enterprise Value | $-9,379,253.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.26 |
| Beta | 3.01 |
| Outstanding Shares | 45,801,927 |
Return
| Return on Equity | 365.28% |
|---|---|
| Return on Assets | -82.95% |
| Return on Invested Capital | -77.84% |
Valuation & Multiples
| P/E Ratio | -0.13 |
|---|---|
| PEG | -0.28 |
| Price to Sales | - |
| Price to Book Ratio | -0.03 |
| Enterprise Value to Revenue | -24.05 |
| Enterprise Value to EBIT | 0.46 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 20, 2026
EPS Estimate
$-0.10
Average shareholder expectationRevenue Estimate
$1.40 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.49%▲ 0.00% |
|---|---|
| Total Invested | $74,826▼ 42.37% |
| Investors Holding | 40% |
ESG Score
No data
About Iterum Therapeutics Plc
7 employeesIterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of peopl...